CTL019

Phase 3Biologic

Novartis

CTL019 is one of 22 biologic programs targeting B-cell acute lymphoblastic leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell Acute Lymphoblastic LeukemiaRecruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 3

Recruiting

Competition

Competitive Landscape

28 competitors in B-Cell Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Fludara

8 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

10 4

Blincyto

Amgen

Phase 2

4 5

Tisagenlecleucel

Novartis

Phase 2

1 6

YK012

EExcyte Biopharma Ltd

Phase 2

1 7

Erbitux

IImclone

Phase 1

1 8

CTL019

Novartis

Phase 3

2 9

Actemra

Roche

Preclinical

1 10

Inaticabtagene Autoleucel

JJuventas Cell Therapy Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT04094311

Q4 2027

Phase 2Active, not recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT03876769

Clinical

Trials by Indication[1]

Efficacy and Safety3 trials

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Completed· Novartis logo

Novartis·Phase 2·NCT02228096·75 enrolled

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

Withdrawn·—·Phase 2·NCT02167360

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Completed· Novartis logo

Novartis·Phase 2·NCT02435849·80 enrolled

B-cell acute lymphoblastic leukemia2 trials

A Phase IIIb Study of the Safety and Efficacy of Tisagenlecleucel Out of Specification for Commercial Release in Patients Who Are Consistent With the Label Indication

Recruiting· Novartis logo

Novartis·Phase 3·NCT04094311·200 enrolled

A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT03876769·121 enrolled

Acute Lymphoblastic Leukemia1 trial

Phase III B in Acute Lymphoblastic Leukemia

Completed· Novartis logo

Novartis·Phase 3·NCT03123939·69 enrolled

Lymphoma1 trial

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Terminated·UUniversity of Cologne·Phase 2·NCT04161118·3 enrolled

DLBCL1 trial

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available· Novartis logo

Novartis··NCT03601442

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for CTL019. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CTL019 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CTL019. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Novartis

CTL019

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Efficacy and Safety3 trials

B-cell acute lymphoblastic leukemia2 trials

Acute Lymphoblastic Leukemia1 trial

Lymphoma1 trial

DLBCL1 trial

References

Drug Info

Quick Facts

Related News